Page 34 - Read Online

Feng et al. Hepatoma Res 2021;7:3 I http://dx.doi.org/10.20517/2394-5079.2020.107 Page 15 of 15

79. Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat
Med 2013;19:329-36.
80. Moehler M, Heo J, Lee HC, et al. Vaccinia-based oncolytic immunotherapy pexastimogene devacirepvec in patients with advanced
hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology
2019;8:1615817.
81. Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat
Med 2013;19;329-36.
82. Moehler M, Heo J, Lee HC, et al. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced
hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology
2019;8:1615817.
83. Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver
cancer: a phase I trial. Lancet Oncol 2008;9:533-42.
84. Rizell M, Eilard MS, Andersson M, et al. Phase 1 trial with the cell-based immune primer ilixadencel, alone, and combined with
sorafenib, in advanced hepatocellular carcinoma. Front Oncol 2019;9:19.
85. Ning N, Pan Q, Zheng F, et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res 2012;7:1853-64.
86. Johnston MP, Khakoo SI. Immunotherapy for hepatocellular carcinoma: current and future. World J Gastroenterol 2019;25:2977-89.
87. Gustafsson K, Ingelsten M, Bergqvist L, Nyström J, Andersson B, Karlsson-Parra A. Recruitment and activation of natural killer cells in
vitro by a human dendritic cell vaccine. Cancer Res 2008;68:5965-71.
88. Shang N, Figini M, Shangguan J, et al. Dendritic cells based immunotherapy. Am J Cancer Res 2017;7:2091-102.
89. Rizell M, Sternby Eilard M, Andersson M, Andersson B, Karlsson-Parra A, Suenaert P. Phase 1 trial with the cell-based immune primer
ilixadencel, alone, and combined with sorafenib, in advanced hepatocellular carcinoma. Front Oncol 2019;9:19.
90. Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood
2010;116:1035-44.
91. Jiang Z, Jiang X, Chen S, et al. Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular
carcinoma. Front Immunol 2016;7:690.
92. Wang Y, Chen M, Wu Z, et al. CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial. Oncoimmunology
2018;7:e1440169.
93. Li D, Li N, Zhang YF, et al. Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic
hepatocellular carcinomas in mice. Gastroenterology 2020;158:2250-65.e20.
94. Liu X, Wen J, Yi H, et al. Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth
with reduced cytokine release. Ther Adv Med Oncol 2020;12:1758835920910347.
95. Sun B, Yang D, Dai H, et al. Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells. Cancer Immunol Res
2019;7:1813-23.
96. Zhang RY, Wei D, Liu ZK, et al. Doxycycline inducible chimeric antigen receptor T cells targeting CD147 for hepatocellular carcinoma
therapy. Front Cell Dev Biol 2019;7:233.
97. Morgan RA, Johnson LA, Davis JL, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and
development of adoptive cell therapy for glioma. Hum Gene Ther 2012;23:1043-53.
98. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28,
inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 2004;172:104-13.
99. Yau T, Kang YK, Kim TY, et al. Efficacy and safety of Nivolumab plus Ipilimumab in patients with advanced hepatocellular carcinoma
previously treated with Sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol 2020;e204564.
100. Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N
Engl J Med 2020;382:1894-905.